Webinars and Symposia
- COVID-19 and pulmonary hypertension
- COVID-19 and myocarditis: reality of fiction?
- EACVI symposium on multimodality imaging (MMI) in COVID-19: From diagnosis to long term follow-up
- Cardiovascular involvement in COVID-19 patients: multimodality imaging for diagnosis, risk stratification and management
- CV biomarkers in COVID-19
- BP measurement at the time of COVID-19. The role of home BP monitoring
- Maintaining CV research and interventional services for patients during COVID-19
- The impact of ´long COVID´ on cardiovascular disease – BigData@Heart
- Heart failure patient management in the time of COVID-19
- Role of contrast echocardiography in hospitalised patients with COVID-19
- CRT: COVID-19 and cardiovascular medicine
- Acute Cardiovascular Care during the COVID-19 pandemic
- EAPCI webinar - COVID-19 and cardiovascular interventions: Current situation and future management. New experiences from across Europe
- EACVI webinar on COVID-19
- EACVI webinar - COVID-19: how to use and interpret lung ultrasound
- Recommendations for cardiac imaging in COVID-19
Infographics
Infographic: Medication and COVID-19
Based on the ESC TV video 'COVID-19 and cardiovascular drugs' with Prof. Garratt Fitzgerald and Prof. Barbara Casadei.
Position statements
- COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology
- Performing elective cardiac invasive procedures during the COVID-19 outbreak: EAPCI position statement
- COVID-19 in ACHD: a position paper from the ESC Working Group of ACHD, and the ISACHD
- Endothelial dysfunction in COVID-19: a position paper of the ESC WG for Atherosclerosis and Vascular Biology, and the ESC CBCS
- EAPCI Position Statement on invasive management of ACS during the COVID-19 pandemic
- Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the HFA
- Management of HF patients with COVID‐19: a joint position paper of the Chinese HF Association & National HF Committee and HFA
- The collateral damage of COVID-19: cardiovascular disease, the next pandemic wave
- Consensus document of the ESC Council of Cardio-Oncology on routine cardiotoxicity echo screening for chemotherapy patients during COVID-19
- Position statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers
Editorials and commentaries
From the European Heart Journal
- Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity
- Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital
- The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world
- Sharpening focus through wider collaboration: evolving heterogeneity in the bi-directional relationship between cardiovascular disease and COVID-19
- Pulmonary embolism, COVID, and bleeding risk in acute coronary syndromes: a Focus Issue on thrombosis and antithrombotic treatment
- Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?
- The evolution of cardiovascular COVID-19 research
- The Janus of COVID-19: from registry data to prospective studies
- Is COVID-19 the deadliest event of the last century?
- The central role of amygdala in stress-related cardiac diseases and an update on long-COVID
- Old and new enemies: psychological stress, occupational stress, COVID-19, and a glimpse of the future
- C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?
- Poor time data impacts on in-hospital resuscitation of COVID-19 patients
- What we (don’t) know about myocardial injury after COVID-19
- Continuity of treatment with ACEi or ARBs for COVID-19 patients supported by a randomised trial
- The collateral cardiovascular damage of COVID-19: only history will reveal the depth of the iceberg
- COVID-19, the wake-up call for implementing sex and gender in CVD
- Cardiac arrest occurrence during COVID-19 pandemic: direct and indirect consequences
- COVID 19: in the eye of the cytokine storm
- Complex interactions with the arrhythmic profile and the clinical course of patients with CVD
- Conflicting results on remdesivir efficacy in hospitalised COVID-19 patients: comment on ACTT-1 trial
- RV: a forgotten essential chamber that may be involved in the cardiac complications of COVID-19
- Implications of renal ACE2 expression in the age of COVID-19
- New data on soluble ACE2 in patients with Afib: a potential value for treatment
- Adapting to survive: Are ‘classic’ clinical trials at risk for extinction in the post-COVID era?
- How overinterpretation of scientific findings can fuel media sensationalism and spread misinformation
- Compromised STEMI reperfusion strategy in the era of COVID-19 pandemic: pros and cons
- STEMI in COVID-19 patients: thrombolysis-first approach could yield more risk than benefit
- Virtual medical education during the COVID-19 pandemic: how to make it work
- How does COVID-19 kill at home and what should we do about it?
- Understanding COVID-19: in the end it is the endothelium—what else?
- STAR evidence evaluation of viral fulminant myocarditis: Specificity, Timeliness, Accessibility, Risk
- Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?
- Should AFib be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?
- ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19
- Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19
- COVID-19 and pulmonary embolism: an unwanted alliance
- Effects of COVID-19 lockdown strategies on management of atrial fibrillation
- ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
- Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?
- The saga continues: is COVID-19 a cardiopulmonary disease?
- Renin–angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs
- Acute coronary syndrome in the time of the COVID-19 pandemic
- Renin–angiotensin–aldosterone system dysregulation and severe acute respiratory syndrome
- Renin–angiotensin system and SARS-CoV-2 infection: there is a before and after
- Myocardial injury in severe COVID-19 infection
- Does epicardial fat contribute to COVID-19 myocardial inflammation?
- Epicardial adipose tissue: fuel for COVID-19-induced cardiac injury?
- RAAS dysregulation and SARS-CoV-2 infection
- At the heart of COVID-19
- Plasma angiotensin-converting enzyme 2: biomarker in heart failure with implications for COVID-19
- SARS-CoV-2 receptor ACE2 expression in the heart: cause of a post-pandemic wave of heart failure?
- Statin therapy and SAR-COV-2: an available and potential therapy?
- Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?
- Acute myocardial injury, MINOCA, or myocarditis?
- Immune-mediated mechanism in coronavirus fulminant myocarditis
- Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19
- Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts
From the European Heart Journal - CardioPulse
- Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19?
- Adult Congenital Heart Disease Academy 2021 live meeting—first international in-person cardiology meeting since COVID-19 outbreak
- Transforming community cardiology practice to virtual visits: innovation at Cleveland Clinic during the COVID-19 pandemic
- The 2020 Olympic/Paralympic Games and COVID-19 in Japan
- Can the US COVID-19 response advance equity in cardiovascular health?
- Waiting for the light at the end of the COVID-19 tunnel: best and worst moments 1 year into the pandemic
- Maintaining high standards of clinical research during the COVID-19 pandemic: insights from an excellence clinical research centre
- Interventional cardiology’s cross-departmental effort with production of reusable PPE during the early phase of COVID-19 pandemic
- COVID-19 and the heart: insights from the National Societies of Cardiology Journals
- Ongoing impact of COVID-19 on cardiovascular care - one year after: insights from leading cardiologists
- COVID-19 and emissions: An opportunity for sustainable global health
- Professor Anthony H. Gershlick: loss of a prominent interventional cardiology leader
- Technology-enabled cardiology training and education in the COVID-19 era and beyond
- From a cardiology institute to a COVID centre in Mexico: cardiology residents in training testimonial
- Response to COVID-19 in a large academic centre in South Africa
- Hydroxychloroquine confers no mortality benefit in hospitalised patients with COVID-19
- ‘Corona’ versus ‘coronary’: the similarities and differences of COVID-19 and CAD
- Plasma donor: a cardiologist's experience
- ER during COVID-19: importance of safe and secure access
- The effects of COVID-19 on general cardiology in Italy
- The stethoscope: a potential vector for COVID-19?
- COVID-19 and continuity of CV care: challenges and potential solutions
- Lessons learnt during COVID-19. A message from outgoing ESC President B. Casadei
- Avoiding the termination of Adaptive COVID-19 Treatment Trial (ACTT)
- The role of cardiology subspecialties in times of crisis
- COVID-19 and CVD: leading cardiologists' views and perspectives
- COVID-19 pandemic: a sentiment analysis
- From presential to online only medical conferences: an example from China
- Fact or fiction on RAAS inhibitors
- Acute coronary syndromes in developing countries during the pandemic: Egyptian example
- COVID-19 testing: A discussion from Italy on why, how, and when to test for SARS-COV-2 virus
- Where have all the myocardial infarctions gone during lockdown?
- EHRA 2020 during COVID-19 days
- Regulating drugs, medical devices, and diagnostic tests in the EU: early lessons
- COVID-19 pandemic in India: Is the curve now flat?
- COVID-19 and Katrina: Recalcitrant racial disparities
- COVID-19 and the healthcare workers
- The ‘Black Death’ and the physician at the time of COVID-19
- Czech Republic and low COVID-19 mortality in the heart of Europe: possible explanations
- Acute coronary syndromes during COVID-19
- Return to sports after COVID-19 infection: Do we have to worry about myocarditis?
- Changes in the work mode of cardiologists during the COVID-19 epidemic in Wuhan
- Heart Team Meetings during COVID-19
- COVID-19 and congenital heart disease in perspective
- Restructuring the CAS course at the University of Zürich during the COVID-19 pandemic
- Trying times for heart failure trials during the COVID-19 pandemic
- TeleCheck-AF for COVID-19
- Don’t throw the stethoscope away! The value of the stethoscope over ultrasound equipment
- Denominator matters in estimating COVID-19 mortality rates
- Personal experiences in Bergamo
- Strategies to control COVID-19 and future pandemics in Africa and around the globe
- The battle against COVID-19: mortality in Italy
- A call for cooperative action from the EU-Cardio RNA COST action
- Priorities for cath labs in the COVID-19 tsunami
- Donning and doffing of personal protective equipment (PPE) for angiography during the COVID-19 crisis
- Health system, public health, and economic implications of managing COVID-19 from a CV perspective
- Key words to be adopted for COVID-19 research: A return to simple, large, randomized trials
- CAPACITY-COVID: a European registry to determine the role of CVD in the COVID-19 pandemic
- Experiences and lesson strategies from the COVID-19 outbreak in China, by ‘on the scene’ cardiologists
- Recommendations from Peking for the management of acute MI during the COVID-19 outbreak
- Initial COVID-19 affecting cardiac patients in China
From Cardiovascular Research
- Racial/ethnic health disparities in cardiovascular disease during the COVID-19 pandemic: revisiting a long-lasting problem
- The battle of testing in COVID-19: the secrets of victory against the virus
- The post-pandemic legacy: the breakthrough of digital health and telemedicine
- COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial
- The endothelium as Achilles’ heel in COVID-19 patients
- Mobile cardiology during the COVID-19 outbreak
- Hypertension and SARS-Cov-2 infection: is inflammation the missing link?
- Endothelial barrier integrity in COVID-19 hyperinflammation: does platelet function matter?
- Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic
- Cardiovascular and immunological implications of social distancing in the context of COVID-19
- SARS-CoV-2 mRNA in endomyocardial biopsies of patients with suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab
- Decreased MI admissions during COVID times: what can we learn?
- COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction
- Inside the heart of COVID-19
From European Heart Journal – Quality of Care & Clinical Outcomes
- Myocardial injury: a future challenge for long-COVID-19 complications
- Targeted atrial fibrillation (AF) detection in COVID-19 vaccination clinics
- Second wave and second opportunity: capitalising on CV research activity during the COVID-19 pandemic
- Reshaping cardiology amidst COVID-19: prioritising medical education
- Cumulative hospitalization deficit for cardiovascular disorders in Germany during the COVID-19 pandemic
- Will the COVID-19 epidemic reshape cardiology?
- Emergency admissions and interventional treatments for heart failure and cardiac arrhythmias in Germany
- Where have the ST-segment elevation myocardial infarctions gone during COVID-19 lockdown?
- ACS undergoing PCI in the COVID-19 era: Delayed symptom onset to hospital presentation
- Cardiology after COVID-19: Quo Vademus?
- Where have the STEMIs gone during COVID-19 lockdown?
- A marker of systemic inflammation or direct cardiac injury: Should cardiac troponin levels be monitored?
From European Heart Journal - Cardiovascular Pharmacotherapy
- Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens with COVID-19
- Thromboprophylaxis for COVID-19-related coagulopathy: what next?
- Tocilizumab, blood cells and mild COVID-19: Delayed vascular protection by interleukin blockade?
- What is linking COVID-19 and endothelial dysfunction? 2020 AHA Scientific Sessions update
- The association of hypertension and diabetes pharmacotherapy with COVID-19 severity
- COVID-19: how things change in a while
- Outcomes of RAAS blockers in patients with COVID-19
- Systemic fibrinolysis for acute PE complicating ARDS in severe COVID-19
- Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19 in critically ill elderly patients
- Protective association of angiotensin blockade with influenza: A result of immortal time bias?
- Statin therapy in COVID-19 infection: much more than a single pathway
- Antihypertensive drugs in COVID-19 infection
- Continuation vs discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19
- Time to treatment still matters in ST-elevation myocardial infarction
- The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19
- Cardiac safety and potential efficacy: reasons for minocycline in place of azithromycin in COVID-19
- Sacubitril/valsartan in COVID-19 patients: the need for trials
- Anticoagulation in COVID-19
- Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)
- Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety
- Statin therapy in COVID-19 infection
- Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
- Speculation is not evidence: antihypertensive therapy and COVID-19
From the European Heart Journal - Digital Health
- Insights from Twitter about novel COVID-19 symptoms
- COVID-19: practical considerations on rapid initiation of remote care in chronic cardiac patients
From European Heart Journal - Cardiovascular Imaging
- Haemodynamic response to COVID-19 and its outcome implications
- Going after COVID-19 myocarditis
- Takotsubo cardiomyopathy and COVID-19 infection
- Reopening echocardiography services to care for our patients, including the COVID-19 patients
- The day after tomorrow: echocardiography laboratories after the COVID-19 outbreak
- An international, multicentre survey of echocardiographic abnormalities in COVID-19 patients
- Subclinical coronary artery disease in COVID-19 patients
- Why, when, and how to use lung ultrasound during COVID-19: enthusiasm and caution
From EP Europace
- Brugada syndrome and COVID-19 vaccines
- How simple ideas forged in the fire of adversity can change healthcare: telehealth for atrial fibrillation during the COVID 19 pandemic
- SARS-CoV-2 and electrocardiography: is electrocardiography a predictor of mortality?—Authors’ reply
- SARS-CoV-2 and electrocardiography: is electrocardiography a predictor of mortality?
From ESC Heart Failure
- A call for telehealth application for heart failure patients during the COVID-19 pandemic
- The other side of the coin: ‘centralization’ against ‘optimization’ in COVID‐19 pandemic
- Impact of COVID‐19 on inpatient referral of AHF: a single‐centre experience from the SW of the UK
- Insights into HF hospitalisations, management, and services during and beyond COVID‐19
- Hypothetical dysfunction of the ENaC may justify neurohumoral blockade in COVID-19
- An increase in AHF offsets the reduction in ACS during COVID‐19 outbreak
- Distribution, infrastructure, and expertise of HF and cardio‐oncology clinics in a developing network
- Being responsible for someone else: a shared duty for parents and HF specialists
- COVID‐19 pandemic: no increase of takotsubo syndrome occurrence despite high‐stress conditions
- Heart transplantation management in northern Italy during COVID‐19: single‐centre experience
From European Journal of Heart Failure
- Myocardial work and vascular dysfunction are partially improved at twelve months after COVID-19 infection
- Recovery of Cardiac Function Following COVID-19
- Reply letter to: Letter regarding the article ‘Circulating cardiovascular microRNAs in critically ill COVID-19 patients’
- COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article ‘Circulating cardiovascular microRNAs in critically ill COVID-19 patients’
- HFpEF and COVID-19: which comes first, the chicken or the egg? REPLY
- HFpEF and COVID-19: which comes first, the chicken or the egg?
- March 2021 at a glance: focus on epidemiology, prevention and COVID‐19
- Reply to: The hyperdynamic circulatory profile of patients with COVID‐19‐related AVDS
- RAASi and COVID‐19: nearing the end of a media‐fuelled controversy
- COVID‐19 ARDS: Intriguing hemodynamics of an intriguing syndrome
- The hyperdynamic circulatory profile of patients with COVID‐19‐related AVDS
- COVID‐19, Myocarditis, and the other side of the bed
- Hospitalisations for HF and mortality risk during the COVID-19 pandemic
- Transforming heart failure and cardio‐oncology care during COVID‐19
- COVID‐19: Getting to the Heart of the Matter
- June 2020 at a glance: focus on COVID‐19, quality of life and comorbidities
- Heart failure hospitalisations during the COVID-19 pandemic
- Decreases in acute heart failure hospitalizations during COVID‐19
- Surviving the first COVID-19 wave and learning lessons for the second
- Heart failure related hospitalisation & management during COVID-19 are we ready to reflect? – REPLY
- Heart failure related hospitalisation & management during COVID-19: are we ready to reflect?
- Deceases in acute heart failure hospitalizations during COVID-19
- Excess out-of-hospital deaths during COVID-19: evidence of pulmonary embolism as a main determinant
- Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience
- Cardio-oncology services during the COVID-19 pandemic: Practical considerations and challenges
- Dilemma of RAS Blockers in COVID-19: Insights on lung fluid handling and gas exchange
- Care for patients with ventricular assist devices and suspected COVID‐19 infection
- SARS-CoV2-related myocarditis-like syndroms: Shakespeare´s question: What´s in a name?
- Experience of remote cardiac care in COVID‐19 pandemic: the V-LAP™ device in advanced heart failure
- Preparing for the tsunami or the way towards flattening the curve, the Greek perspective
From European Heart Journal - Acute Cardiovascular Care
- The COVID-19 pandemic: challenge and chance for a scientific association
- Cardiovascular biomarkers in COVID-19
- United we stand, divided we fall
- Cardiac arrest in the COVID-19 era
From European Journal of Preventive Cardiology
- Letter on Incidence and prognosis of COVID-19 among heart transplant recipients: a systematic review and meta-analysis
- COVID-19 in heart transplant patients: is there a cause for concern?
- COVID-19 pandemic and cardiovascular disease: the double sentence
- Exercise rehabilitation associates with lower mortality and hospitalisation in CVD patients with COVID-19
- Cardiovascular rehabilitation in the COVID-19 era: ‘a phoenix arising from the ashes?’
- The strange case of hydroxychloroquine and COVID-19
- Association of Afib and left atrial volume index with mortality in patients with COVID-19 pneumonia
- Providing comprehensive cardiac rehabilitation during and after the COVID-19 pandemic
- Amiodarone in COVID-19: let’s not forget its potential for pulmonary toxicity
- Fatty liver disease in obese patients with COVID-19: a tale of two pandemics?
- Telehealth during COVID-19 pandemic: will the future last?
- The morbidity and mortality of COVID-19 are associated with ABO and Rh blood groups
- EAPC call to action for cardiac telerehabilitation in the COVID-19 pandemic
- Editor’s presentation: ‘Les liaisones dangerouses. The heart in the time of COVID-19’
- COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead
- Sport and exercise during and beyond the COVID-19 pandemic
- C3 polymorphisms: an important immunological confounder on the COVID-19 spread and outcome
- C3 and ACE1 polymorphisms are more important confounders in comparison with ABO polymorphism
- Cardiology practice in the COVID-19 era
- Physical activity/inactivity and COVID-19
- Comparison of cardiovascular metabolic characteristics and impact on COVID-19 and MERS
- Les liaisons dangereuses and the danger of deductions: interplay between CVD and COVID-19
- Confronting the reality of COVID
- Future-proofing cardiac rehabilitation: Transitioning services to telehealth during COVID-19
- ABO blood group predisposes to COVID-19 severity and cardiovascular diseases
- Cost-effectiveness of rivaroxaban plus aspirin for prevention of ischaemic events in patients with CVD
- SARS CoV2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers
- 2019 CORONAVIRUS: What are the implications for cardiology?
From European Journal of Cardiovascular Nursing
- Remote cardiac rehabilitation services and the digital divide: implications for elderly populations during the COVID19 pandemic
- Breaking pandemic chain reactions: telehealth psychosocial support in CVD during COVID-19
- Accelerated importance of eHealth literacy in the COVID-19 outbreak and beyond
- Palliative care: Essential support for patients with heart failure in the COVID-19 pandemic
- Impact of the pandemic on ongoing cardiovascular research projects: considerations and adaptations
- Flexibility and safety in times of coronavirus disease 2019: Implications for nurses and allied professionals
From European Heart Journal - Supplements
- ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)
- ANMCO POSITION PAPER: The reorganization of cardiology in times of the SARS-CoV-2 pandemic
- Cardiovascular disease in the COVID-19 pandemic: risk and risk reduction
- What can health systems learn from COVID-19?
- COVID-19 impact upon patients, staff, and on the future practices of PCI
- COVID-19 and paediatric patient involvement (cardiovascular aspects)
- COVID-19: patients with stroke or risk of stroke
- Advanced remote care for HF in times of COVID-19 using an implantable PA pressure sensor: the new normal
- Left atrial appendage occlusion in COVID-19 times
- Impact of the COVID-19 pandemic: a perspective from industry
- ANMCO POSITION PAPER: Management of COVID-19 patients needing urgent EP and/or ES procedures
- ANMCO POSITION PAPER: Role of cardiology managing health needs in the post-Covid-19 era
- ANMCO POSITION PAPER: Network organisation for the treatment of ACS patients during the pandemic
- ANMCO POSITION PAPER: In-hospital and outpatient cardiology consultations during the pandemic
- ANMCO POSITION PAPER: The cardiological clinical activities in the transition phase of the pandemic
From EuroIntervention
- STEMI outcomes in the era of COVID-19: reaffirmation of an unfortunate reality
- Immediate and long-term impact of the COVID-19 pandemic on CV clinical trials
- Minimalist” TAVI during the COVID-19 pandemic: previously optional but now a necessity
- The people left behind: refining priorities for health care during and after the pandemic
- Best practice in left main intervention, physiology-guided complete revascularisation in STEMI - EAPCI guidance
Our mission: To reduce the burden of cardiovascular disease.